Catalyst Pharmaceuticals Inc. (CPRX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Catalyst Pharmaceuticals ...

    NASDAQ: CPRX · Real-Time Price · USD
    19.30
    0.17 (0.89%)
    At close: Sep 26, 2025, 1:13 PM

    Catalyst Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 491.73M 398.2M 214.2M 140.83M
    Cost of Revenue
    		 68.84M 84.53M 34.39M 21.88M
    Gross Profit
    		 422.89M 313.67M 179.81M 118.95M
    Operating Income
    		 195.12M 86.81M 101.84M 52.38M
    Interest Income
    		 n/a n/a n/a 282K
    Pretax Income
    		 216.26M 94.51M 104.72M 52.67M
    Net Income
    		 163.89M 71.41M 83.08M 39.48M
    Selling & General & Admin
    		 177.74M 133.71M 58.18M 49.63M
    Research & Development
    		 12.65M 93.15M 19.79M 16.94M
    Other Expenses
    		 37.38M n/a n/a 282K
    Operating Expenses
    		 227.76M 259.43M 77.97M 66.56M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 10M 86.69M 29.47M 26.15M
    Cost & Expenses
    		 296.61M 311.39M 112.36M 88.45M
    Income Tax Expense
    		 52.37M 23.1M 21.64M 13.19M
    Shares Outstanding (Basic)
    		 118.46M 106.28M 103.37M 103.38M
    Shares Outstanding (Diluted)
    		 124.94M 113.75M 111.38M 107.8M
    EPS (Basic)
    		 1.38 0.67 0.80 0.38
    EPS (Diluted)
    		 1.31 0.63 0.75 0.37
    EBITDA
    		 232.9M 119.69M 101.84M 52.38M
    EBIT
    		 195.12M 86.81M 104.72M 52.67M
    Depreciation & Amortization
    		 37.77M 32.88M 1.49M 484K

    Add to Watchlist